Paramita Basu

Pre-Clinical Sciences Department, New York College of Podiatric Medicine, USA

Publications

• Research Article   
  Reconsidering Chloroquine and Hydroxychloroquine in Treatment of COVID-19: Lessons learnt
  Author(s): Paramita Basu*, Parijat Das, Dianna Levin, Jenna Bloemer, Opemipo Akin-Adejim and Keith Veltri
  
  The pandemic of Coronavirus Disease 2019 (COVID-19) caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been difficult to manage globally due to the absence of proven effective therapeutic options. While there are numerous studies that are currently underway to develop new medications or vaccines to cure the deadly disease and to prevent its spread, the time needed to accomplish this is long. In view of the urgency of this situation, there is a need to also consider the possibility of identifying a cure using the existing medications with known safety and toxicity profiles. So there has been a renewed interest in studying the therapeutic effect of available drugs with anti-viral and anti-inflammatory activity, like Hydroxychloroquine (HCQ) and Chloroquine (CQ), which have been used successfully for a long time to treat malaria and rheumatic disorders, .. Read More»